应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02186 绿叶制药
未开盘 09-26 16:08:25
3.190
+0.080
+2.57%
最高
3.190
最低
3.070
成交量
1,534万
今开
3.110
昨收
3.110
日振幅
3.86%
总市值
120.00亿
流通市值
120.00亿
总股本
37.62亿
成交额
4,838万
换手率
0.41%
流通股本
37.62亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
绿叶制药09月25日主力资金流入287万元 连续3日加仓
市场透视 · 09-25 16:16
绿叶制药09月25日主力资金流入287万元 连续3日加仓
绿叶制药09月24日获主力加仓708万元 环比增加5346.15%
市场透视 · 09-24 16:15
绿叶制药09月24日获主力加仓708万元 环比增加5346.15%
绿叶制药09月13日获主力加仓198万元 环比增加890.00%
市场透视 · 09-13
绿叶制药09月13日获主力加仓198万元 环比增加890.00%
绿叶制药09月10日遭主力抛售464万元 环比增加274.19%
市场透视 · 09-10
绿叶制药09月10日遭主力抛售464万元 环比增加274.19%
南向资金9月4日净卖出绿叶制药712.85万股 连续3日减持
市场透视 · 09-05
南向资金9月4日净卖出绿叶制药712.85万股 连续3日减持
绿叶制药:中期业绩超预期 目标价上调
和讯网 · 09-04
绿叶制药:中期业绩超预期 目标价上调
高盛:维持绿叶制药(02186)“沽售”评级 目标价上调至3.99港元
智通财经 · 09-03
高盛:维持绿叶制药(02186)“沽售”评级 目标价上调至3.99港元
《大行》高盛微升绿叶制药(02186.HK)目标价至3.99元 中期盈利胜预期
阿斯达克财经 · 09-03
《大行》高盛微升绿叶制药(02186.HK)目标价至3.99元 中期盈利胜预期
【券商聚焦】东北证券上调绿叶制药(02186)至“买入”评级 多款新药实现获批 有望打开海外业务增长空间
金吾财讯 · 09-03
【券商聚焦】东北证券上调绿叶制药(02186)至“买入”评级 多款新药实现获批 有望打开海外业务增长空间
花旗:一举上调绿叶制药(02186)评级至“买入” 目标价升至4港元
智通财经 · 09-02
花旗:一举上调绿叶制药(02186)评级至“买入” 目标价升至4港元
《大行》花旗一举升绿叶制药(02186.HK)评级至“买入” 上调目标价至4元
阿斯达克财经 · 09-02
《大行》花旗一举升绿叶制药(02186.HK)评级至“买入” 上调目标价至4元
异动解读 | 绿叶制药中期业绩大涨 股价单日暴涨5.24%
异动解读 · 08-29
异动解读 | 绿叶制药中期业绩大涨 股价单日暴涨5.24%
绿叶制药(02186)上涨5.24%,报3.01元/股
金融界 · 08-29
绿叶制药(02186)上涨5.24%,报3.01元/股
绿叶制药绩后涨超4% 中期股东应占溢利同比增加158.60%
新浪港股 · 08-29
绿叶制药绩后涨超4% 中期股东应占溢利同比增加158.60%
港股异动 | 绿叶制药(02186)绩后涨超3% 中期股东应占溢利3.88亿元 同比增超1.5倍
智通财经 · 08-29
港股异动 | 绿叶制药(02186)绩后涨超3% 中期股东应占溢利3.88亿元 同比增超1.5倍
绿叶制药发布中期业绩 股东应占溢利3.88亿元同比增加158.6%
新浪港股 · 08-29
绿叶制药发布中期业绩 股东应占溢利3.88亿元同比增加158.6%
绿叶制药(02186)发布中期业绩 股东应占溢利3.88亿元 同比增加158.6%
智通财经 · 08-28
绿叶制药(02186)发布中期业绩 股东应占溢利3.88亿元 同比增加158.6%
绿叶制药发布2024年中期业绩:净利劲增201%,5款新药密集获批
美通社 · 08-28
绿叶制药发布2024年中期业绩:净利劲增201%,5款新药密集获批
绿叶制药08月23日遭主力抛售326万元 环比增加183.48%
市场透视 · 08-23
绿叶制药08月23日遭主力抛售326万元 环比增加183.48%
绿叶制药08月20日主力资金流出408万元 连续7日减仓
自选股智能写手 · 08-20
绿叶制药08月20日主力资金流出408万元 连续7日减仓
暂无数据
公司概况
公司名称:
绿叶制药
所属市场:
SEHK
上市日期:
--
主营业务:
绿叶制药集团有限公司是一家主要从事开发、生产、推广及销售药品的投资控股公司。公司及其子公司通过四大分部运营:肿瘤药物分部、心血管系统药物分部、消化与代谢药物分部和其他分部。该公司的主要产品包括用于癌症的化学治疗的备紫杉醇类制剂,用于实体肿瘤的放射治疗的注射用化合物,用于治疗高脂血症治疗的中药,用于治疗二型糖尿病的阿卡波糖胶囊,用于治疗老年痴呆症的卡巴拉汀透皮贴片等。产品以力扑素,希美纳,血脂康,麦通纳,贝希等品牌销售。该公司通过其子公司还从事提供合约研究及程序开发业务。该公司主要在中国内地运营业务。
发行价格:
--
{"stockData":{"symbol":"02186","market":"HK","secType":"STK","nameCN":"绿叶制药","latestPrice":3.19,"timestamp":1727338105032,"preClose":3.11,"halted":0,"volume":15335600,"delay":0,"floatShares":3761670643,"shares":3761670643,"eps":0.15935385,"marketStatus":"未开盘","marketStatusCode":0,"change":0.08,"latestTime":"09-26 16:08:25","open":3.11,"high":3.19,"low":3.07,"amount":48375727,"amplitude":0.038585,"askPrice":3.19,"askSize":75500,"bidPrice":3.18,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":0.22846237387699225,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1727400600000},"adr":0,"adjPreClose":3.11,"dividendRate":0.020013,"openAndCloseTimeList":[[1727314200000,1727323200000],[1727326800000,1727337600000]],"volumeRatio":1.7143582049341595,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02186/tweets","defaultTab":"tweets","newsList":[{"id":"2470280909","title":"绿叶制药09月25日主力资金流入287万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2470280909","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470280909?lang=zh_cn&edition=full","pubTime":"2024-09-25 16:16","pubTimestamp":1727252207,"startTime":"0","endTime":"0","summary":"09月25日, 绿叶制药股价涨0.97%,报收3.11元,成交金额3510万元,换手率0.30%,振幅2.27%,量比1.65。绿叶制药今日主力资金净流入287万元,连续3日净流入,上一交易日主力净流入708万元,今日环比减少59.46%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为41.67%,平均涨幅为1.74%。该股近5个交易日上涨5.41%,主力资金累计净流入497万元;近20日主力资金累计净流出102万元,其中净流出天数为8日。该股主力净额占比0.02%,港股市场排名190/2636。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409251617339f151c73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409251617339f151c73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1606","BK1191","02186"],"gpt_icon":0},{"id":"2469882459","title":"绿叶制药09月24日获主力加仓708万元 环比增加5346.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2469882459","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469882459?lang=zh_cn&edition=full","pubTime":"2024-09-24 16:15","pubTimestamp":1727165759,"startTime":"0","endTime":"0","summary":"09月24日, 绿叶制药股价涨1.99%,报收3.08元,成交金额2935万元,换手率0.26%,振幅2.65%,量比1.83。绿叶制药今日主力资金净流入708万元,上一交易日主力净流入13万元,今日环比增加5346.15%。该股近5个交易日上涨4.41%,主力资金累计净流入209万元;近20日主力资金累计净流出519万元,其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409241616389f125f00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409241616389f125f00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02186","BK1606","BK1583"],"gpt_icon":0},{"id":"2467688710","title":"绿叶制药09月13日获主力加仓198万元 环比增加890.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2467688710","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467688710?lang=zh_cn&edition=full","pubTime":"2024-09-13 16:16","pubTimestamp":1726215406,"startTime":"0","endTime":"0","summary":"09月13日, 绿叶制药股价涨0.68%,报收2.95元,成交金额2025万元,换手率0.18%,振幅2.39%,量比0.91。绿叶制药今日主力资金净流入198万元,连续3日净流入,上一交易日主力净流入20万元,今日环比增加890.00%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为50.00%,平均涨幅为2.00%。该股近5个交易日下跌3.61%,主力资金累计净流出342万元;近20日主力资金累计净流出2770万元,其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240913161741956263f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240913161741956263f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02186","BK1583","BK1606","BK1191"],"gpt_icon":0},{"id":"2466148583","title":"绿叶制药09月10日遭主力抛售464万元 环比增加274.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2466148583","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466148583?lang=zh_cn&edition=full","pubTime":"2024-09-10 16:15","pubTimestamp":1725956152,"startTime":"0","endTime":"0","summary":"09月10日, 绿叶制药股价跌1.33%,报收2.96元,成交金额2130万元,换手率0.19%,振幅1.33%,量比0.79。绿叶制药今日主力资金净流出464万元,连续3日净流出,上一交易日主力净流出124万元,今日环比增加274.19%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为43.75%,平均跌幅为2.31%。该股近5个交易日下跌2.63%,主力资金累计净流出1096万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出3482万元,其中净流出天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409101616169ef17615&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409101616169ef17615&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02186","BK1191","BK1583","BK1606"],"gpt_icon":0},{"id":"2465056680","title":"南向资金9月4日净卖出绿叶制药712.85万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2465056680","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465056680?lang=zh_cn&edition=full","pubTime":"2024-09-05 09:30","pubTimestamp":1725499813,"startTime":"0","endTime":"0","summary":"9月4日,南向资金减持绿叶制药712.85万股连续3日减持。截止当日收盘,港股通共持有绿叶制药137813.15万股,占流通股36.62%。绿叶制药近5个交易日上涨4.90%,港股通累计减持2853.20万股;近20个交易日上涨3.81%,港股通累计减持5781.25万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409050931379ee1243e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409050931379ee1243e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1606","02186","BK1583"],"gpt_icon":0},{"id":"2464324447","title":"绿叶制药:中期业绩超预期 目标价上调","url":"https://stock-news.laohu8.com/highlight/detail?id=2464324447","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464324447?lang=zh_cn&edition=full","pubTime":"2024-09-04 17:36","pubTimestamp":1725442605,"startTime":"0","endTime":"0","summary":"【9 月 4 日,高盛发布研究报告称】绿叶制药上半年产品销售表现一般,销售总额同比上升 6%至 30.8 亿元,低于高盛预测的 32.7 亿元。 但因期内销售开支同比减少 24%,带动盈利增长近 1.6 倍至 3.88 亿元,超出该行预期的 2.08 亿元,中期业绩表现超预期。 展望未来,该行估计绿叶制药将致力于重组销售团队,更注重提升经营效率,期待政策环境趋稳,销售开支持续在未来几个季度减少。相应将今年盈利预测上调至 1.96 亿元,维持 2025 及 2026 年盈利预测基本不变,目标价由 3.95 港元上调至 3.99 港元,维持“沽售”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409041748479edf610c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409041748479edf610c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02186"],"gpt_icon":0},{"id":"2464271868","title":"高盛:维持绿叶制药(02186)“沽售”评级 目标价上调至3.99港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2464271868","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464271868?lang=zh_cn&edition=full","pubTime":"2024-09-03 17:06","pubTimestamp":1725354395,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,高盛发布研究报告称,维持绿叶制药(02186)“沽售”评级,目标价由3.95港元上调至3.99港元。公司上半年产品销售表现平平,销售总额同比升6%至30.8亿元人民币,低于高盛预测的32.7亿元人民币,但由于期内销售开支同比减少24%,带动盈利增长近1.6倍至3.88亿元人民币,超出该行预期的2.08亿元人民币,令中期业绩表现胜预期。展望未来,该行估计绿叶制药致力于重组销售团队,更专注于提升经营效率,憧憬政策环境趋向稳定,销售开支持续于未来几个季度减少,相应将今年盈利预测上调至1.96亿元人民币,维持2025及2026年盈利预测基本不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1178675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02186"],"gpt_icon":0},{"id":"2464180829","title":"《大行》高盛微升绿叶制药(02186.HK)目标价至3.99元 中期盈利胜预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2464180829","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464180829?lang=zh_cn&edition=full","pubTime":"2024-09-03 15:59","pubTimestamp":1725350340,"startTime":"0","endTime":"0","summary":"高盛发表研究报告指,绿叶制药上半年产品销售表现平平,销售总额按年升6%至30.8亿元人民币,低于高盛预测的32.7亿元人民币,但由于期内销售开支按年减少24%,带动盈利增长近1.6倍至3.88亿元人民币,超出该行预期的2.08亿元人民币,令中期业绩表现胜预期。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220711102728108_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220711102728108_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1378789/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02186"],"gpt_icon":0},{"id":"2464269728","title":"【券商聚焦】东北证券上调绿叶制药(02186)至“买入”评级 多款新药实现获批 有望打开海外业务增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2464269728","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464269728?lang=zh_cn&edition=full","pubTime":"2024-09-03 15:49","pubTimestamp":1725349791,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东北证券发研报指,绿叶制药 发布2024年中期业绩公告。该行表示,公司上半年净利润增速超200%,主要归因于营收的增长和费用管控得当。今年3款新药产品已实现获批,包括ERZOFRI美国获批治疗精神分裂症,进一步打开海外业务增长空间,金悠平和美比瑞今年6月国内获批上市,将持续放量贡献国内销售额收入。该行预计公司24-26年实现收入64.76/71.23/86.47亿元,每股收益为0.22/0.28/0.38元,给予公司“买入”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200915/YWJkMTExMDAwMDkzNTUyODE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/YWJkMTExMDAwMDkzNTUyODE=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1943599","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186","000686"],"gpt_icon":0},{"id":"2464888419","title":"花旗:一举上调绿叶制药(02186)评级至“买入” 目标价升至4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2464888419","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464888419?lang=zh_cn&edition=full","pubTime":"2024-09-02 16:25","pubTimestamp":1725265506,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,花旗发布研究报告称,一举将绿叶制药(02186)评级由“沽售”上调至“买入”,由于集团营运效率及杠杆比率下降,令利润率呈长期上升趋势,上调2024/25/26年每股盈测39%、27%及26%,目标价由2.4港元上调至4港元。报告中称,公司受惠于新产品增加及四个主要成熟产品的稳定销售,管理层预计2025/27年的营业额分别超过70亿及100亿元人民币,又重申2027财年的净利润率改善至20%。公司目标是在2024财年降低15亿人民币的债务,并节省1亿人民币的财务费用。上半年的盈利显示,公司正在改善盈利能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1177989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02186"],"gpt_icon":0},{"id":"2464079729","title":"《大行》花旗一举升绿叶制药(02186.HK)评级至“买入” 上调目标价至4元","url":"https://stock-news.laohu8.com/highlight/detail?id=2464079729","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464079729?lang=zh_cn&edition=full","pubTime":"2024-09-02 11:56","pubTimestamp":1725249360,"startTime":"0","endTime":"0","summary":"花旗发表研究报告指,绿叶制药受惠于新产品增加及四个主要成熟产品的稳定销售,管理层预计2025/27年的营业额分别超过70亿及100亿元人民币,又重申2027财年的净利润率改善至20%。公司目标是在2024财年降低15亿人民币的债务,并节省1亿人民币的财务费用。该行表示,由于集团营运效率及杠杆比率下降,令利润率呈长期上升趋势,上调2024/25/26年每股盈测39%、27%及26%,目标价相应由2.4元上调至4元,一举将集团的评级由“沽售”上调至“买入”。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220711102728108_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220711102728108_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1378387/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02186"],"gpt_icon":0},{"id":"1170605690","title":"异动解读 | 绿叶制药中期业绩大涨 股价单日暴涨5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170605690","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170605690?lang=zh_cn&edition=full","pubTime":"2024-08-29 11:40","pubTimestamp":1724902836,"startTime":"0","endTime":"0","summary":"港股绿叶制药今日公布2024年中期业绩,业绩表现大幅向好,成为推动股价大涨的关键因素。投资者对公司未来发展前景充满信心,其股价盘中一度大涨逾6.5%,收盘时涨幅达5.24%,报2.97港元。根据中期报告显示,绿叶制药集团在2024年上半年实现营业收入30.75亿元人民币,较去年同期增长5.87%。更为亮眼的是,归属母公司股东净利润高达3.88亿元,同比大幅增长158.6%,每股基本盈利达10.31分人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"gpt_icon":0},{"id":"2463427066","title":"绿叶制药(02186)上涨5.24%,报3.01元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2463427066","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463427066?lang=zh_cn&edition=full","pubTime":"2024-08-29 10:59","pubTimestamp":1724900364,"startTime":"0","endTime":"0","summary":"8月29日,绿叶制药盘中上涨5.24%,截至10:59,报3.01元/股,成交5213.88万元。关键经营数据显示,2021年,公司产品销售覆盖全国30个省、自治区和直辖市,通过约1000名销售和营销人员以及约1780家经销商网络,产品销往19330多家医院,同时在国际市场覆盖80个国家或地区。截至2024年中报,绿叶制药营业总收入30.75亿元、净利润3.88亿元。8月28日,2024财年中报归属股东应占溢利3.878亿人民币,同比增长158.6%,基本每股收益0.1031人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/29105942856819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1606","BK1191","02186"],"gpt_icon":1},{"id":"2463342999","title":"绿叶制药绩后涨超4% 中期股东应占溢利同比增加158.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463342999","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463342999?lang=zh_cn&edition=full","pubTime":"2024-08-29 09:58","pubTimestamp":1724896687,"startTime":"0","endTime":"0","summary":"绿叶制药(02186)绩后上涨4.55%,现报2.99港元,成交额2447.64万港元。\n 绿叶制药发布截至2024年6月30日止6个月业绩,该集团期内取得收入30.75亿元(人民币,下同),同比增加5.87%;母公司拥有人应占溢利3.88亿元,同比增加158.6%;每股基本盈利10.31分。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-29/doc-incmhmeq1204075.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-29/doc-incmhmeq1204075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1606","02186","BK1583","BK1191"],"gpt_icon":0},{"id":"2463250074","title":"港股异动 | 绿叶制药(02186)绩后涨超3% 中期股东应占溢利3.88亿元 同比增超1.5倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2463250074","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463250074?lang=zh_cn&edition=full","pubTime":"2024-08-29 09:40","pubTimestamp":1724895650,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,绿叶制药(02186)绩后涨超3%,截至发稿,涨2.80%,报2.94港元,成交额1045.96万港元。消息面上,绿叶制药发布截至2024年6月30日止6个月业绩,该集团期内取得收入30.75亿元(人民币,下同),同比增加5.87%;母公司拥有人应占溢利3.88亿元,同比增加158.6%;每股基本盈利10.31分。公告称,截至2024年6月30日,集团拥有27项处于不同发展阶段的中国在研产品。该等在研药物包括18种肿瘤产品、5种中枢神经系统产品及4种其他产品。此外,集团在美国、欧洲和日本拥有11种处于不同开发阶段的在研产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1174377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02186","BK1606","BK1191"],"gpt_icon":0},{"id":"2463444238","title":"绿叶制药发布中期业绩 股东应占溢利3.88亿元同比增加158.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463444238","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463444238?lang=zh_cn&edition=full","pubTime":"2024-08-29 08:07","pubTimestamp":1724890057,"startTime":"0","endTime":"0","summary":"绿叶制药(02186)发布截至2024年6月30日止6个月业绩,该集团期内取得收入30.75亿元(人民币,下同),同比增加5.87%;母公司拥有人应占溢利3.88亿元,同比增加158.6%;每股基本盈利10.31分。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-29/doc-incmhewv9895491.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-29/doc-incmhewv9895491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1606","BK1191","02186","BK1583"],"gpt_icon":0},{"id":"2462460931","title":"绿叶制药(02186)发布中期业绩 股东应占溢利3.88亿元 同比增加158.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462460931","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462460931?lang=zh_cn&edition=full","pubTime":"2024-08-28 23:22","pubTimestamp":1724858534,"startTime":"0","endTime":"0","summary":"智通财经APP讯,绿叶制药 发布截至2024年6月30日止6个月业绩,该集团期内取得收入30.75亿元,同比增加5.87%;母公司拥有人应占溢利3.88亿元,同比增加158.6%;每股基本盈利10.31分。截至2024年6月30日,集团在中国共获得272项专利并有66项专利处于申请阶段,在海外共获得552项专利并有123项专利处于申请阶段。集团已经建立一个庞大的全国性销售及分销网络,截至2024年6月30日,其产品销往全国31个省、自治区和直辖市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1174167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1606","BK1583","BK1191","02186"],"gpt_icon":0},{"id":"2462983064","title":"绿叶制药发布2024年中期业绩:净利劲增201%,5款新药密集获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2462983064","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462983064?lang=zh_cn&edition=full","pubTime":"2024-08-28 23:18","pubTimestamp":1724858280,"startTime":"0","endTime":"0","summary":"上海2024年8月28日 /美通社/ -- 绿叶制药集团发布2024年中期业绩及截至目前的业务进展。其中,产品销售费用率为31%,大幅下降9个百分点。该板块自2021年以来持续回升,新产品放量逐步抵消政策端对成熟产品的影响。今年,集团即将迎来3款肿瘤产品获批上市,将协同公司肿瘤领域已上市产品,迅速提升肿瘤业务营收与利润贡献。绿叶制药集团管理层表示:\"得益于新产品放量和公司治理策略的高效实施,集团盈利能力显著增强。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4493442_ZH93442_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["CNS","02186","BK1606","BK4135","BK1191","BK1583"],"gpt_icon":0},{"id":"2461355918","title":"绿叶制药08月23日遭主力抛售326万元 环比增加183.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461355918","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461355918?lang=zh_cn&edition=full","pubTime":"2024-08-23 16:16","pubTimestamp":1724400967,"startTime":"0","endTime":"0","summary":"08月23日, 绿叶制药股价跌1.07%,报收2.77元,成交金额2315万元,换手率0.22%,振幅1.43%,量比0.93。绿叶制药今日主力资金净流出326万元,上一交易日主力净流出115万元,今日环比增加183.48%。该股近5个交易日下跌4.47%,主力资金累计净流出1924万元;近20日主力资金累计净流出2721万元,其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082316172195b752df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082316172195b752df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1606","02186","BK1583"],"gpt_icon":0},{"id":"2460302130","title":"绿叶制药08月20日主力资金流出408万元 连续7日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2460302130","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460302130?lang=zh_cn&edition=full","pubTime":"2024-08-20 16:16","pubTimestamp":1724141790,"startTime":"0","endTime":"0","summary":"08月20日, 绿叶制药股价跌1.39%,报收2.83元,成交金额2185万元,换手率0.20%,振幅2.44%,量比0.95。绿叶制药今日主力资金净流出408万元,连续7日净流出,上一交易日主力净流出360万元,今日环比增加13.33%。该股近5个交易日下跌2.08%,主力资金累计净流出1168万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流出2095万元,其中净流出天数为13日。该股主力净额占比0.04%,港股市场排名2566/2638。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082016165895a9e891&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082016165895a9e891&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1606","BK1191","BK1583","02186"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luye.cn","stockEarnings":[{"period":"1week","weight":0.0563},{"period":"1month","weight":0.1076},{"period":"3month","weight":0.1815},{"period":"6month","weight":0.1685},{"period":"1year","weight":-0.1139},{"period":"ytd","weight":-0.1448}],"compareEarnings":[{"period":"1week","weight":0.1061},{"period":"1month","weight":0.1147},{"period":"3month","weight":0.1245},{"period":"6month","weight":0.2045},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1688}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"绿叶制药集团有限公司是一家主要从事开发、生产、推广及销售药品的投资控股公司。公司及其子公司通过四大分部运营:肿瘤药物分部、心血管系统药物分部、消化与代谢药物分部和其他分部。该公司的主要产品包括用于癌症的化学治疗的备紫杉醇类制剂,用于实体肿瘤的放射治疗的注射用化合物,用于治疗高脂血症治疗的中药,用于治疗二型糖尿病的阿卡波糖胶囊,用于治疗老年痴呆症的卡巴拉汀透皮贴片等。产品以力扑素,希美纳,血脂康,麦通纳,贝希等品牌销售。该公司通过其子公司还从事提供合约研究及程序开发业务。该公司主要在中国内地运营业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.026366},{"month":2,"riseRate":0.3,"avgChangeRate":0.013725},{"month":3,"riseRate":0.4,"avgChangeRate":-0.015714},{"month":4,"riseRate":0.5,"avgChangeRate":-0.00409},{"month":5,"riseRate":0.3,"avgChangeRate":-0.034213},{"month":6,"riseRate":0.3,"avgChangeRate":-0.003238},{"month":7,"riseRate":0.6,"avgChangeRate":-0.000283},{"month":8,"riseRate":0.181818,"avgChangeRate":-0.034124},{"month":9,"riseRate":0.636364,"avgChangeRate":0.050164},{"month":10,"riseRate":0.6,"avgChangeRate":0.01699},{"month":11,"riseRate":0.6,"avgChangeRate":0.04117},{"month":12,"riseRate":0.4,"avgChangeRate":0.009706}],"exchange":"SEHK","name":"绿叶制药","nameEN":"LUYE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.0","shortVersion":"4.28.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"绿叶制药(02186)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供绿叶制药(02186)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"绿叶制药,02186,绿叶制药股票,绿叶制药股票老虎,绿叶制药股票老虎国际,绿叶制药行情,绿叶制药股票行情,绿叶制药股价,绿叶制药股市,绿叶制药股票价格,绿叶制药股票交易,绿叶制药股票购买,绿叶制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"绿叶制药(02186)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供绿叶制药(02186)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}